BRPI0408767B8 - inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica - Google Patents
inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêuticaInfo
- Publication number
- BRPI0408767B8 BRPI0408767B8 BRPI0408767A BRPI0408767A BRPI0408767B8 BR PI0408767 B8 BRPI0408767 B8 BR PI0408767B8 BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 B8 BRPI0408767 B8 BR PI0408767B8
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- reverse transcriptase
- formula
- treatment
- mediated diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
"inibidores da transcriptase reversa não-nucleosídeos i para o tratamento de doenças mediadas pelo hiv". a presente invenção refere-se a novos compostos heterocíclicos de fórmula (i), em que r^ 1^-r^ 4^, x^ 1^ e x^ 2^ são como definidos no sumário e sais e solvatos farmaceuticamente aceitáveis destes, métodos para inibir ou modular a transcriptase reversa do vírus da imunodeficiência humana (hiv) com compostos de fórmula (i), composições farmacêuticas contendo a fórmula i misturadas com pelo menos um solvente, veículo ou excipiente e processos para se preparar os compostos de fórmula i. o compostos são úteis para o tratamento de distúrbios, em que o hiv e os vírus geneticamente relacionados estão envolvidos.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122016023941-1A BR122016023941B1 (pt) | 2003-03-24 | 2004-03-22 | Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45713003P | 2003-03-24 | 2003-03-24 | |
US60/457,130 | 2003-03-24 | ||
PCT/EP2004/002995 WO2004085411A1 (en) | 2003-03-24 | 2004-03-22 | Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0408767A BRPI0408767A (pt) | 2006-03-28 |
BRPI0408767B1 BRPI0408767B1 (pt) | 2017-10-31 |
BRPI0408767B8 true BRPI0408767B8 (pt) | 2021-05-25 |
Family
ID=33098199
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016023941-1A BR122016023941B1 (pt) | 2003-03-24 | 2004-03-22 | Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica |
BRPI0408767A BRPI0408767B8 (pt) | 2003-03-24 | 2004-03-22 | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016023941-1A BR122016023941B1 (pt) | 2003-03-24 | 2004-03-22 | Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica |
Country Status (20)
Country | Link |
---|---|
US (2) | US7208509B2 (pt) |
EP (1) | EP1608633B1 (pt) |
JP (1) | JP4708329B2 (pt) |
KR (1) | KR101122456B1 (pt) |
CN (1) | CN100588650C (pt) |
AR (1) | AR043673A1 (pt) |
AU (1) | AU2004224153B2 (pt) |
BR (2) | BR122016023941B1 (pt) |
CA (1) | CA2518437C (pt) |
CL (1) | CL2004000590A1 (pt) |
CO (1) | CO5601029A2 (pt) |
ES (1) | ES2574580T3 (pt) |
HR (1) | HRP20050830A2 (pt) |
IL (1) | IL170343A (pt) |
MX (1) | MXPA05010210A (pt) |
NO (1) | NO334095B1 (pt) |
NZ (1) | NZ541829A (pt) |
RU (1) | RU2342367C2 (pt) |
TW (1) | TW200505441A (pt) |
WO (1) | WO2004085411A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100516065C (zh) * | 2004-04-01 | 2009-07-22 | 安万特药物公司 | 1,3,4-二唑-2-酮作为PPAR-δ调节剂 |
US8293778B2 (en) | 2004-07-27 | 2012-10-23 | Roche Palo Alto Llc | Heterocyclic antiviral compounds |
WO2006010545A1 (en) | 2004-07-27 | 2006-02-02 | F. Hoffmann-La Roche Ag | Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors |
CN101180280A (zh) * | 2005-03-24 | 2008-05-14 | 弗·哈夫曼-拉罗切有限公司 | 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物 |
AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
JP2009510013A (ja) * | 2005-09-30 | 2009-03-12 | エフ.ホフマン−ラ ロシュ アーゲー | Nnrt阻害剤 |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
JP2009519308A (ja) * | 2005-12-15 | 2009-05-14 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン |
EP3696171A1 (en) | 2006-07-07 | 2020-08-19 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
CL2007002105A1 (es) * | 2006-07-21 | 2008-02-22 | Hoffmann La Roche | Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u |
MX2009001198A (es) | 2006-08-16 | 2009-02-11 | Hoffmann La Roche | Inhibidores no nucleosidicos de la transcriptasa inversa. |
TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
ES2603617T3 (es) * | 2007-02-23 | 2017-02-28 | Gilead Sciences, Inc. | Moduladores de propiedades farmacocinéticas de la terapéutica |
BRPI0810496A2 (pt) * | 2007-04-09 | 2018-11-06 | Hoffmann La Roche | inibidores de transcriptase reversa de não-nucleosídeo |
EP2164835B1 (en) | 2007-05-30 | 2012-12-12 | F. Hoffmann-La Roche AG | Process for preparing triazolones |
ES2542153T3 (es) | 2007-05-30 | 2015-07-31 | F. Hoffmann-La Roche Ag | Inhibidores no nucleósidos de la transcriptasa inversa |
WO2008157330A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
WO2008157273A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
JP2010530863A (ja) * | 2007-06-22 | 2010-09-16 | エフ.ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としての尿素及びカルバマート誘導体 |
WO2009005811A1 (en) * | 2007-07-03 | 2009-01-08 | Yale University | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) |
KR101610607B1 (ko) * | 2007-12-21 | 2016-04-07 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
EP2552902B1 (en) * | 2010-03-30 | 2015-03-11 | Merck Canada Inc. | Non-nucleoside reverse transcriptase inhibitors |
CU23896B1 (es) * | 2010-04-01 | 2013-05-31 | Ct De Ingeniería Genética Y Biotecnología | Método para inhibir la replicación del vih en células de mamíferos |
JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
CN104230929B (zh) * | 2013-06-19 | 2015-11-18 | 华东师范大学 | 一种非核苷类hiv-1反转录酶抑制剂 |
ES2828951T3 (es) | 2014-04-01 | 2021-05-28 | Merck Sharp & Dohme | Profármacos de inhibidores de la transcriptasa inversa del VIH |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274185A (en) | 1963-10-08 | 1966-09-20 | S E Massengill Company | Phthalazine derivatives |
US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
JP2542880B2 (ja) | 1986-12-19 | 1996-10-09 | メレルダウファーマスーティカルズ インコーポレーテッド | 5−アリ―ル−3h−1,2,4,−トリアゾ―ル−3−オン類の抗痙攣剤としての用途 |
JP2593084B2 (ja) | 1986-12-19 | 1997-03-19 | メレルダウファーマスーティカルズ インコーポレーテッド | 5−アリールー3h−1,2,4−トリアゾールー3−オン類の神経変性障害の処置への用途 |
US5436252A (en) | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
US4942236A (en) | 1987-09-30 | 1990-07-17 | American Home Products Corporation | 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents |
US4826990A (en) | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US5103014A (en) | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
US4966909A (en) | 1989-12-20 | 1990-10-30 | Merrell Dow Pharmaceuticals | 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants |
US5331002A (en) | 1990-04-19 | 1994-07-19 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
US5641796A (en) | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
EP1330442B1 (en) * | 2000-10-30 | 2011-01-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
UA82048C2 (uk) | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
JP2002275165A (ja) * | 2001-01-12 | 2002-09-25 | Sumitomo Pharmaceut Co Ltd | トリアゾール誘導体 |
-
2004
- 2004-03-18 TW TW093107292A patent/TW200505441A/zh unknown
- 2004-03-22 BR BR122016023941-1A patent/BR122016023941B1/pt active IP Right Grant
- 2004-03-22 ES ES04722259.1T patent/ES2574580T3/es not_active Expired - Lifetime
- 2004-03-22 CL CL200400590A patent/CL2004000590A1/es unknown
- 2004-03-22 BR BRPI0408767A patent/BRPI0408767B8/pt active IP Right Grant
- 2004-03-22 WO PCT/EP2004/002995 patent/WO2004085411A1/en active Application Filing
- 2004-03-22 AR ARP040100937A patent/AR043673A1/es not_active Application Discontinuation
- 2004-03-22 AU AU2004224153A patent/AU2004224153B2/en not_active Expired
- 2004-03-22 JP JP2006504792A patent/JP4708329B2/ja not_active Expired - Lifetime
- 2004-03-22 CN CN200480006480A patent/CN100588650C/zh not_active Expired - Lifetime
- 2004-03-22 KR KR1020057017771A patent/KR101122456B1/ko active IP Right Grant
- 2004-03-22 RU RU2005132632/04A patent/RU2342367C2/ru active
- 2004-03-22 CA CA2518437A patent/CA2518437C/en not_active Expired - Lifetime
- 2004-03-22 EP EP04722259.1A patent/EP1608633B1/en not_active Expired - Lifetime
- 2004-03-22 MX MXPA05010210A patent/MXPA05010210A/es active IP Right Grant
- 2004-03-22 NZ NZ541829A patent/NZ541829A/en unknown
- 2004-03-23 US US10/807,766 patent/US7208509B2/en active Active
-
2005
- 2005-08-18 IL IL170343A patent/IL170343A/en active IP Right Grant
- 2005-09-15 NO NO20054264A patent/NO334095B1/no unknown
- 2005-09-21 HR HR20050830A patent/HRP20050830A2/xx not_active Application Discontinuation
- 2005-09-21 CO CO05095661A patent/CO5601029A2/es not_active Application Discontinuation
-
2007
- 2007-02-02 US US11/701,881 patent/US7348345B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408767B8 (pt) | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica | |
BRPI0407591A (pt) | inibidores de transcriptase reversa de não-nucleosìdeo | |
BRPI0408704A (pt) | benzil-piridazinonas como inibidores de transcriptase reversa | |
BRPI0208811B8 (pt) | derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos | |
BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
BRPI0516972A (pt) | composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto | |
BR0209267A (pt) | Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf) | |
BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
BRPI0213522C1 (pt) | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto | |
BRPI0415759A (pt) | compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BR0015056A (pt) | Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico | |
BR0316081A (pt) | Derivados de 2-piridona como inibidores de elastase de neutrófilo | |
BR0208572A (pt) | Derivados de aminopiperidina | |
BR0017063A (pt) | Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las | |
ECSP034547A (es) | Derivados de pirazol para el tratamiento de enfermedades virales | |
BRPI0518117A (pt) | uso de um derivado de piridotienopirimidina, composição farmacêutica, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de cura pela inibição da fosfodiesterase 4 e produto de combinação | |
BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
BR0109900A (pt) | Derivados de pirolidina farmaceuticamente ativos, uso de derivados de pirolidina, composição farmacêutica e processo para preparação de um derivado de pirolidina | |
BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
BR0210158A (pt) | Derivados de pirazol como inibidores da transcriptase reversa do hiv | |
BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
BR0308786A (pt) | Derivados de ftalimido como inibidores da monoamina oxidase b | |
BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |